ES2032397T3 - Procedimiento para preparar una composicion en dispersion solida de la sustancia fr-900506 - Google Patents

Procedimiento para preparar una composicion en dispersion solida de la sustancia fr-900506

Info

Publication number
ES2032397T3
ES2032397T3 ES198787103716T ES87103716T ES2032397T3 ES 2032397 T3 ES2032397 T3 ES 2032397T3 ES 198787103716 T ES198787103716 T ES 198787103716T ES 87103716 T ES87103716 T ES 87103716T ES 2032397 T3 ES2032397 T3 ES 2032397T3
Authority
ES
Spain
Prior art keywords
solid dispersion
preparing
substance
procedure
dispersion composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787103716T
Other languages
English (en)
Inventor
Yoshio Ueda
Fumio Shimojo
Yasuo Shimazaki
Kazutake Kado
Toshiyasu Honbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2032397T3 publication Critical patent/ES2032397T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Reinforced Plastic Materials (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Colloid Chemistry (AREA)

Abstract

UNA COMPOSICION EN DISPERSION SOLIDA, QUE COMPRENDE 17-ALIL-1,14-DIHIDROXI-12-[2-(4-HIDROXI-3METOXICICLOHEXIL) -1-METILVINIL] 23,25-DIMETOXI-13, 19,21, 27-TERTRAMETIL -11,28-DIOXA-4-AZATRICICLO [22.3.1.0 4,9] OCTACOS-18- ENE-2,3,10,16-TERTRAONA Y UN POLIMERO SOLUBLE EN AGUA, Y PROCEDIMIENTOS PARA PREPARAR DICHA COMPOSICION EN DISPERSION SOLIDA.
ES198787103716T 1986-04-02 1987-03-14 Procedimiento para preparar una composicion en dispersion solida de la sustancia fr-900506 Expired - Lifetime ES2032397T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608080A GB8608080D0 (en) 1986-04-02 1986-04-02 Solid dispersion composition

Publications (1)

Publication Number Publication Date
ES2032397T3 true ES2032397T3 (es) 1993-02-16

Family

ID=10595572

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787103716T Expired - Lifetime ES2032397T3 (es) 1986-04-02 1987-03-14 Procedimiento para preparar una composicion en dispersion solida de la sustancia fr-900506

Country Status (16)

Country Link
US (1) US4916138A (es)
EP (1) EP0240773B1 (es)
JP (1) JPS62277321A (es)
KR (2) KR950007209B1 (es)
AT (1) ATE73327T1 (es)
CA (1) CA1302279C (es)
DE (1) DE3777223D1 (es)
DK (1) DK174979B1 (es)
ES (1) ES2032397T3 (es)
GB (1) GB8608080D0 (es)
GR (1) GR3004124T3 (es)
HK (1) HK6397A (es)
IE (1) IE59712B1 (es)
MX (1) MX9202945A (es)
RU (1) RU1826977C (es)
UA (1) UA13209A (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
ES2043766T3 (es) * 1987-11-11 1994-01-01 Pharmascience Lab Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua.
JPH02206A (ja) * 1987-11-11 1990-01-05 Fujisawa Pharmaceut Co Ltd エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
FR2640137A1 (fr) * 1988-12-08 1990-06-15 Texinfine Sa Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
ZA905202B (en) * 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
DK0489181T3 (da) * 1990-07-19 1996-11-18 Otsuka Pharma Co Ltd Fast præparat
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
ES2134860T3 (es) * 1992-11-18 1999-10-16 Fujisawa Pharmaceutical Co Preparacion farmaceutica de accion prolongada.
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
CN1137680C (zh) 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
ZA9710927B (en) 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
JP4221762B2 (ja) * 1997-04-11 2009-02-12 アステラス製薬株式会社 医薬組成物
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
MXPA01011052A (es) 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
CA2399198A1 (en) 2000-02-18 2001-08-23 Christopher Carreras Motilide compounds
US6750047B2 (en) * 2000-08-21 2004-06-15 Kosan Biosciences, Inc. Fermentation and purification of migrastatin and analog
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US6989131B2 (en) * 2002-03-12 2006-01-24 Uop Llc Catalytic reactor with integral evaporator
SI1532131T1 (sl) * 2002-08-29 2009-04-30 Pfizer Motilidne spojine
BRPI0412329A (pt) * 2003-07-09 2006-09-05 Chong Kun Dang Pharm Corp dispersão sólida de tacrolimus e método de processar a mesma
US7994214B2 (en) 2003-08-29 2011-08-09 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
ES2376238T3 (es) * 2003-08-29 2012-03-12 Veloxis Pharmaceuticals A/S Composiciones de liberación modificada comprendiendo tacrolimus.
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008528448A (ja) * 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
CA2611031A1 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2779041A1 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
JP5264716B2 (ja) 2006-06-09 2013-08-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物および方法
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
JP5383513B2 (ja) * 2007-03-09 2014-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物ならびに方法
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
PL2167033T4 (pl) 2007-05-30 2018-08-31 Veloxis Pharmaceuticals A/S Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
NZ583689A (en) 2007-09-14 2012-04-27 Univ Michigan F1f0-atpase inhibitors and related methods
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
NZ584842A (en) 2007-11-06 2012-06-29 Univ Michigan Benzodiazepinone compounds useful in the treatment of skin conditions, in particular, psoriasis
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
KR101003042B1 (ko) 2008-03-17 2010-12-21 종근당바이오 주식회사 고순도 타크로리무스의 정제 방법
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
JP2013505258A (ja) 2009-09-18 2013-02-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ベンゾジアゼピノン化合物およびそれを使用する治療方法
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
ES2591352T3 (es) 2010-02-17 2016-11-28 Veloxis Pharmaceuticals A/S Composición de tacrolimus estabilizada
US8900605B2 (en) 2010-06-14 2014-12-02 Ratiopharm Gmbh Solid ivabradine-containing composition
WO2012026896A1 (en) 2010-08-25 2012-03-01 Les Laboratoires Medis Sa Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
KR101243938B1 (ko) * 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
JP6185559B2 (ja) * 2012-04-11 2017-08-23 ダウ グローバル テクノロジーズ エルエルシー 有機希釈剤およびセルロースエーテルを含む組成物
US10610491B2 (en) 2013-09-25 2020-04-07 Dow Global Technologies Llc Composition comprising an organic liquid diluent and a specific hydroxyalkyl methylcellulose
CN105828827A (zh) * 2014-11-21 2016-08-03 杭州领业医药科技有限公司 一种含他克莫司的药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (es) * 1963-10-11
DE1492034A1 (de) * 1965-05-18 1969-02-20 Merck Ag E Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same

Also Published As

Publication number Publication date
MX9202945A (es) 1992-07-01
JPH0536411B2 (es) 1993-05-31
KR890001626A (ko) 1989-03-28
DK140487D0 (da) 1987-03-18
JPS62277321A (ja) 1987-12-02
DK140487A (da) 1987-10-03
EP0240773B1 (en) 1992-03-11
HK6397A (en) 1997-01-24
ATE73327T1 (de) 1992-03-15
GR3004124T3 (es) 1993-03-31
KR870010073A (ko) 1987-11-30
EP0240773A1 (en) 1987-10-14
IE59712B1 (en) 1994-03-23
US4916138A (en) 1990-04-10
KR950007209B1 (ko) 1995-07-04
IE870843L (en) 1987-10-02
DE3777223D1 (de) 1992-04-16
UA13209A (uk) 1997-02-28
DK174979B1 (da) 2004-04-05
GB8608080D0 (en) 1986-05-08
KR950007210B1 (ko) 1995-07-04
CA1302279C (en) 1992-06-02
RU1826977C (ru) 1993-07-07

Similar Documents

Publication Publication Date Title
AU590692B2 (en) 2-azolylmethyl-2-aryl-1, 3-dioxolanes and the salts thereof, processes for the preparation thereof,agents containing same,and the use thereof
AU7452987A (en) Vinylamine copolymer, flocculating agent using the same, and process for preparing same
ES549056A0 (es) Un procedimiento para la preparacion de una dispersion de un polimero acrilico solubre en agua.
ES523560A0 (es) Procedimiento para la (co) polimerizacion de alfa-olefinas en lecho fluidificado.
ES2022339B3 (es) Articulo para transferencia grafica seca, metodo de preparacion y uso.
IT8421343A0 (it) Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti.
AU3045492A (en) Embedding medium structures for use in the preparation of multi-specimen slides for immunohistologic procedures
FI885533A0 (fi) Polymerkomposition foer anvaendning som belaeggning foer elledningar och foerfarande foer belaeggning av elledningar.
EP0406274A4 (en) New, water soluble, antineoplastic derivatives of taxol
AU7042187A (en) 2-azolylmethyl-2-aryl-1, 3-dioxolanes and the salts thereof,processes for the preparation thereof,agents containing same,and the use thereof
NO861979L (no) Uorganisk/polymerfiberkompositt, fremgangsmaate for fremstilling av denne og anvendelse innbefattende dimensjonsstabil separator.
GB8727669D0 (en) Synthetic intraocular lens swellable in swelling agent & method for preparation thereof
ES518588A0 (es) Procedimiento para la preparacion de una dispersion de polimero.
AR243907A1 (es) Metodo para la preparacion de polietilenos de baja o media densidad, de cadena recta.
NO172439C (no) Fremgangsmaate for fremstilling av tetrazolforbindelser ogforbindelse som anvendes i fremgangsmaaten
IT8619670A0 (it) Composti stabilizzanti polimerici solidi e procedimento per la loro preparazione.
AU590400B2 (en) 2-azolylmethyl-2-aryl-1, 3-dioxolanes and the salts thereof, processes for the preparation thereof, agents containing same, and the use thereof
ES543549A0 (es) Un procedimiento para preparar una composicion polimera que incluye un copolimero de bloques selectivamente hidrogenado un copolimero vinilaromatico y otros.
MX17041A (es) Procedimiento para la preparacion de benzopirano pirazoles.
IL94350A0 (en) Composition,agent and method for activating mammalian t cells
FI900469A7 (fi) Aktiiviaineita vapauttava systeemi, jonka eroosio on säädetty, ja menetelmä sen valmistamiseksi
ES2007265A6 (es) Un metodo para preparar conjugados de indol-portador biologicamente activos.
IT8622780A0 (it) "2-cloro-12-(-3-dimetilammino-2-metilpropil)-12h-dibenzo-/d,g//1,3,6/d iossazocine otticamente attive eprocedimento per la loro preparazione.
BR8901200A (pt) Composicao anti-espuma solida,composicao agroquimica e processo para preparacao das mesmas
ES8302461A1 (es) "un procedimiento para preparar una composicion antipruritica".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 240773

Country of ref document: ES